Shots:
- The P-II study involves assessing Olamkicept (300/600mg, q2w, IV) vs PBO in 91 patients in a ratio (1:1:1) who had active UC with a full Mayo score ≥5, a rectal bleeding subscore ≥1, an endoscopy subscore ≥2, and had an inadequate response with conventional UC therapy
- The study met its 1EPs & 2EPs, demonstrating higher clinical response rates after 12wks. of treatment with 600mg dose & more patients achieved clinical remission and mucosal healing respectively. Olamkicept was well tolerated with the acceptable safety profile
- Olamkicept is the only clinical stage selective IL-6 inhibitor that works through the trans-signaling mechanism
Click here to read full press release/ article | Ref: PRNewswire | Image: i-Mab
The post I-Mab Reports Results of Olamkicept (TJ301) in P-II Study for Ulcerative Colitis first appeared on PharmaShots.
